Debt Reduction and Improved Leverage
Avantor paid down over $200 million of debt, bringing net leverage down to 3.8x. The company expects to achieve adjusted net leverage of less than 3x with proceeds from the clinical services divestiture.
Strong Free Cash Flow and Guidance Increase
Avantor generated over $200 million in free cash flow for the quarter and approximately $550 million year-to-date, raising the full-year guidance to more than $750 million.
Bioprocessing Performance
Bioprocessing sales outperformed expectations, with strong order momentum reinforcing confidence in mid- to high single-digit growth in the fourth quarter.
Successful Divestiture
Avantor successfully closed the divestiture of its clinical services assets, receiving $500 million in after-tax proceeds.
Innovation and Expansion
Avantor launched new products and opened a flagship innovation center in Bridgewater, New Jersey, enhancing capabilities in bioprocessing and laboratory solutions.